AACR 2019 Single agent umbralisib effective for relapsed slowgrowing lymphoma

AACR 2019: Single agent umbralisib effective for relapsed slow-growing lymphoma

07:08 EDT 2 Apr 2019 | ecancermedicalscience

A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead...

More From BioPortfolio on "AACR 2019: Single agent umbralisib effective for relapsed slow-growing lymphoma"